JournalsHub
.online
Find My Journal
BW

Björn E. Wahlin

Karolinska University Hospital SE

ORCID 0000-0003-3566-8847
192
Publications
3,048
Citations
25
H-Index
64
i10-Index
5.38
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Publications

0 total

POST HOC ANALYSIS OF OUTCOMES BY POD24 STATUS FROM THE inMIND STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

L. Sehn, K. Hübel, S. Luminari, C. Scholz, A. Salar - Hematological Oncology, 2025
Cited by 0 Semantic Scholar

POSTER: IBCL-625 Quality of Life (QoL) Outcomes With Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma (R/R FL): Results From a Phase 3, Double-Blind, Randomized, Placebo-Controlled, International, Multicenter Study (inMIND)

P. Strati, Christina Poh, M. Trněný, K. Hübel, S. Luminari - Clinical Lymphoma, Myeloma & Leukemia, 2025
Cited by 0 Semantic Scholar

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial OA

Joshua D Brody, J. Jørgensen, D. Belada, Régis Costello, M. Trněný - Blood, 2025
Cited by 41 Semantic Scholar

IBCL-625: Quality of Life (QoL) Outcomes With Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma (R/R FL): Results From a Phase 3, Double-Blind, Randomized, Placebo-Controlled, International, Multicenter Study (inMIND)

P. Strati, Christina Poh, M. Trněný, K. Hübel, S. Luminari - Clinical Lymphoma, Myeloma & Leukemia, 2025
Cited by 0 Semantic Scholar

OUTCOMES FROM THE PHASE 3 inMIND STUDY OF TAFASITAMAB (TAFA) PLUS LENALIDOMIDE (LEN) AND RITUXIMAB (R) FOR PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)

L. Sehn, K. Hübel, S. Luminari, C. Scholz, A. Salar - Hematological Oncology, 2025
Cited by 2 Semantic Scholar

Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation

Prokop Vodička, T. El‐Galaly, V. Prochazka, C. Flowers, D. Villa - Blood, 2025
Cited by 0 Semantic Scholar

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.

Laurie H Sehn, K. Hübel, S. Luminari, Christian Scholz, A. Salar - The Lancet, 2025
Cited by 5 Semantic Scholar

MOSUNETUZUMAB FOR EARLY RELAPSE OF FOLLICULAR LYMPHOMA IN THE NORDIC COUNTRIES (MERLIN)

M. Brodtkorb, M. Hernberg, M. E. Bjørn, M. Pollari, K. Wader - Hematological Oncology, 2025
Cited by 0 Semantic Scholar

ABCL-275 Epcoritamab + GemOx Induces Deep Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2

R. Córdoba, J. Jørgensen, D. Belada, Régis Costello, M. Trněný - Clinical Lymphoma, Myeloma & Leukemia, 2024
Cited by 1 Semantic Scholar

Epcoritamab + GemOx Induces Deep, Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2

R. Córdoba, J. Jørgensen, D. Belada, Régis Costello, M. Trněný - Clinical Lymphoma, Myeloma & Leukemia, 2024
Cited by 0 Semantic Scholar

Research Topics

Lymphoma Diagnosis and Treatment (143) Chronic Lymphocytic Leukemia Research (67) CAR-T cell therapy research (32) Immune Cell Function and Interaction (28) Viral-associated cancers and disorders (27)

Affiliations

Uppsala University
SE 2022 - 1993
Oslo University Hospital
NO 2011 - 2011
University Hospital of North Norway
NO 2011 - 2011
Swedish Veterinary Agency
SE 1993 - 1993
Karolinska University Hospital
SE 2025 - 1986

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now